Breaking News
Get 40% Off 0
🔎 See NVDA's full ProTips for an instant risks or rewards Claim 40% OFF
Close

Sanofi SA (0O59)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
88.86 +1.65    +1.89%
10:55:25 - Real-time Data. Currency in EUR ( Disclaimer )
  • Volume: 29,301
  • Bid/Ask: 87.85 / 89.64
  • Day's Range: 86.84 - 88.89
Type:  Equity
Market:  United Kingdom
ISIN:  FR0000120578 
SEDOL:  B114ZY6
Sanofi 88.86 +1.65 +1.89%

0O59 Income Statement

 
Assess the Sanofi SA income statement, view the company's financial performance across their assets and liabilities. Select to view either quarterly or annual data.
AnnualQuarterly
InvestingPro Advanced Income Statement
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Revenue 12201 12698 10588 10863
Revenue 10919 11964 9965 10222
Other Revenue, Total 1282 734 623 641
Cost of Revenue, Total 4048 3841 3263 3079
Gross Profit 8153 8857 7325 7784
Total Operating Expenses 10234 9221 9042 8042
Selling/General/Admin. Expenses, Total 2931 2579 2616 2607
Research & Development 1872 1663 1630 1563
Depreciation / Amortization - - - -
Interest Expense (Income) - Net Operating -625 -318 -60 -168
Unusual Expense (Income) - - - -
Other Operating Expenses, Total 2008 1456 1593 961
Operating Income 1967 3477 1546 2821
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets - - 413 -
Other, Net 2216 376 -585 353
Net Income Before Taxes -249 3101 1718 2468
Provision for Income Taxes 309 563 271 459
Net Income After Taxes -558 2538 1447 2009
Minority Interest 313 - 318 -
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items -555 2525 1435 1995
Total Extraordinary Items - - - -
Net Income -555 2525 1435 1995
Total Adjustments to Net Income - - - -
Income Available to Common Excluding Extraordinary Items -555 2525 1435 1995
Dilution Adjustment - - 5.22 -
Diluted Net Income -555 2525 1429.78 1995
Diluted Weighted Average Shares 1253.6 1253.2 1250.6 1249.3
Diluted EPS Excluding Extraordinary Items -0.443 2.01 1.14 1.6
DPS - Common Stock Primary Issue 3.76 - - -
Diluted Normalized EPS 0.688 1.67 0.713 1.4
* In Millions of EUR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SASY Comments

Write your thoughts about Sanofi L
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Boubacar s b Toure
Boubacar s b Toure Mar 11, 2023 1:51
Saved. See Saved Items.
This comment has already been saved in your Saved Items
nzf
Oct 06, 2022 17:00
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will eventually do well because of French strategy. France is at the top table and Sanofi was made up by absorbing others to grow. Look at 20% in a couple of years
Greg Greg
Greg Greg Dec 11, 2020 9:36
Saved. See Saved Items.
This comment has already been saved in your Saved Items
there is no future for it
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email